# Variant Analysis Report #4

**Gene:** PAH

**Variant:** NM_000277.3:c.361T>G

---

<think>
Okay, let's tackle this variant interpretation step by step. The variant in question is PAH: c.361T>G (p.Phe121Val). First, I need to recall the ACMG/AMP 2015 guidelines and ClinGen SVI criteria. 

Starting with the Pathogenic criteria. PVS1 is for loss-of-function variants in genes where LOF is a known disease mechanism. PAH is involved in phenylalanine metabolism, and mutations here cause phenylketonuria (PKU), which is an autosomal recessive disorder. However, this is a missense variant, not a LOF like nonsense or frameshift. So PVS1 doesn't apply here.

Next, PS1: same amino acid change as a known pathogenic variant. The ClinVar entry says "Likely_pathogenic," but I need to check if this exact variant is listed there. If not, PS1 might not be applicable. However, the user mentioned ClinVar lists it as Likely_pathogenic, which might be based on other evidence, but without specific mention of same amino acid change, PS1 might not be met.

PS2: De novo in a patient with no family history. The data here says De novo is N/A, so PS2 isn't applicable.

PS3: Functional studies showing damaging effect. The functional studies are N/A, so PS3 isn't met.

PS4: Increased frequency in patients vs controls. The gnomAD data is all None, so no population data. Without this, PS4 can't be evaluated.

Moving to PM criteria. PM1: located in a hotspot or important domain. PAH has several domains, like the active site. Phe121 is part of the active site? I need to check the protein structure. If this residue is in a critical region, PM1 might apply. But without specific information, it's uncertain. Maybe the ClinGen SVI would have this info, but the user hasn't provided it. So I might have to mark PM1 as not met due to lack of data.

PM2: Absent or very rare in population databases. gnomAD has no data, which could be considered as very rare. However, if the variant is not present in gnomAD, that's a PM2. But the user says "None" for all gnomAD AF, which might mean it's not present. So PM2 is met. The strength would be PM2 since it's absent.

PM3: Trans in a recessive disease. Not applicable here as PM3 is for trans in dominant diseases. Wait, PM3 is for recessive diseases where the variant is found in trans with another pathogenic variant. But the data here doesn't mention that, so PM3 isn't met.

PM4: Change in protein length. This is a missense, so no change in length. PM4 not applicable.

PM5: Same amino acid as other pathogenic variants. If there are other pathogenic variants at Phe121, then PM5 applies. But without that info, can't confirm. The user hasn't provided that, so PM5 is not met.

PM6: De novo but not confirmed. The data says De novo is N/A, so PM6 isn't met.

Now, PP criteria. PP1: Co-segregation in family. No data, so not met.

PP2: Missense in a gene where missense is rare. PAH is a gene where missense variants are common in PKU, but if the gene is known to have few missense variants, PP2 might apply. However, without specific info, it's hard to say. Maybe the ClinGen SVI would have this, but the user hasn't provided it. So PP2 might not be met.

PP3: Multiple computational predictions. CADD is 0.99, REVEL 0.99, which are both high. These are considered strong evidence. So PP3 is met with strong support.

PP4: Phenotype specific to the gene. If the patient has PKU symptoms, then PP4 applies. But the user hasn't provided the patient's phenotype. So without that, PP4 can't be evaluated.

PP5: Classified as pathogenic in a reputable database. ClinVar lists it as Likely_pathogenic, so PP5 is met.

For benign criteria, BA1: AF >5% in population. Since gnomAD has None, BA1 isn't met.

BS1: Higher frequency than expected. No data, so not applicable.

BS2: Seen in healthy adults. No data, so not applicable.

BS3: Functional studies show no effect. No data, so not applicable.

BS4: Lack of segregation. No data, so not applicable.

BP criteria: BP1: Missense in a gene where LOF is the mechanism. PAH is LOF, but this is a missense, so BP1 might not apply. However, if the gene is known to have missense variants, but the user hasn't provided that info. Maybe BP1 isn't met.

BP2: Trans with pathogenic variant. Not applicable here.

BP3: In-frame indel in non-functional region. Not applicable.

BP4: Computational evidence suggests no effect. The CADD and REVEL are high, so BP4 isn't met.

BP5: Alternative molecular evidence. Not applicable.

BP6: Classified as benign in reputable source. Not applicable.

BP7: No splice effect. SpliceAI is N/A, but the variant is a missense, so BP7 might be met. However, the user hasn't provided splice data, so it's uncertain. Maybe BP7 is not applicable.

Now, compiling the criteria. Pathogenic criteria: PM2 (PM2), PP3 (PP3), PP5 (PP5). The ClinVar entry is Likely_pathogenic, which is a PP5. The PM2 is met because the variant is absent in gnomAD. PP3 is strong because of high CADD and REVEL. 

According to the classification rules, if there's one PM2 (moderate) and two PP (PP3 and PP5, which are supporting), but the rules for Likely Pathogenic require at least one PM and one PP. Wait, the rules for Likely Pathogenic are (i) PVS1 + PM, (ii) PS1 + PM, etc. But here, we have PM2 (moderate) and PP3 (supporting) and PP5 (supporting). 

Wait, the user's data has ClinVar as Likely_pathogenic, which is a PP5. So combining PM2 (moderate) and PP5 (supporting) would meet the criteria for Likely Pathogenic. Also, PP3 (supporting) adds more support. 

But according to the rules, for Likely Pathogenic, one PM (PM2) and one PP (PP5) would suffice. So the classification would be Likely Pathogenic. The confidence is high because of the ClinVar classification and the PM2 and PP3/PP5. 

However, the user's data might have missing information, like the exact position of the amino acid in the protein domain. If Phe121 is in a critical domain, PM1 would be met, which would add another moderate criterion. But without that info, PM1 is not considered. 

So the final classification is Likely Pathogenic with high confidence.
</think>

### **1. 병원성 증거 (Pathogenic Evidence)**

#### **A. 매우 강력 (PVS1):**
- **평가:** 미충족  
- **근거:** PVS1은 **loss-of-function (LOF)** 변이 (nonsense, frameshift 등)에 해당하는 유전자에서의 null 변이를 요구합니다. 그러나 이 변이는 **missense** (p.Phe121Val)로, LOF 변이가 아닙니다.  
- **강도:** 미충족  

---

#### **B. 강력 (PS1-PS4):**
- **PS1:**  
  - **평가:** 미충족  
  - **근거:** ClinVar에서 "Likely_pathogenic"으로 분류되었지만, 동일한 아미노산 변화 (p.Phe121Val)가 기존 병원성 변이와 동일한지 명시되지 않았습니다.  

- **PS2:**  
  - **평가:** 미충족  
  - **근거:** De novo 여부는 "N/A"로 제공되지 않았습니다.  

- **PS3:**  
  - **평가:** 미충족  
  - **근거:** 기능 연구 (in vitro/in vivo) 데이터가 제공되지 않았습니다.  

- **PS4:**  
  - **평가:** 미충족  
  - **근거:** gnomAD 데이터는 "None"으로, 환자군과 대조군 간의 유병률 차이를 평가할 수 없습니다.  

---

#### **C. 중등도 (PM1-PM6):**
- **PM1:**  
  - **평가:** 미충족  
  - **근거:** 변이 위치 (p.Phe121)가 PAH 단백질의 중요 기능 도메인 (예: 활성 부위)에 해당하는지에 대한 정보가 제공되지 않았습니다.  

- **PM2:**  
  - **평가:** 충족  
  - **근거:** gnomAD에서 이 변이의 대립유전자 빈도 (AF)가 "None"으로, **집단 데이터베이스에서 극히 드물거나 부재**합니다.  
  - **강도:** PM2  

- **PM3:**  
  - **평가:** 미충족  
  - **근거:** 열성 질환에서 trans에서 병원성 변이와 동반된 사례가 제공되지 않았습니다.  

- **PM4:**  
  - **평가:** 미충족  
  - **근거:** 단백질 길이 변화가 없습니다 (missense).  

- **PM5:**  
  - **평가:** 미충족  
  - **근거:** 동일한 아미노산 위치 (Phe121)에 다른 병원성 미스센스 변이가 존재하는지에 대한 정보가 제공되지 않았습니다.  

- **PM6:**  
  - **평가:** 미충족  
  - **근거:** De novo 여부는 "N/A"로 제공되지 않았습니다.  

---

#### **D. 지지 (PP1-PP5):**
- **PP1:**  
  - **평가:** 미충족  
  - **근거:** 가계 분리 데이터가 제공되지 않았습니다.  

- **PP2:**  
  - **평가:** 미충족  
  - **근거:** PAH는 missense 변이가 흔한 유전자이므로, PP2 (미스센스 변이가 드문 유전자)에 해당하지 않습니다.  

- **PP3:**  
  - **평가:** 충족  
  - **근거:** CADD (0.99)와 REVEL (0.99) 모두 **고위험** 예측을 보여줍니다.  
  - **강도:** PP3  

- **PP4:**  
  - **평가:** 미충족  
  - **근거:** 환자의 표현형/가족력이 PAH와 특이적으로 연관된지에 대한 정보가 제공되지 않았습니다.  

- **PP5:**  
  - **평가:** 충족  
  - **근거:** ClinVar에서 "Likely_pathogenic"으로 분류되어 있습니다.  
  - **강도:** PP5  

---

### **2. 양성 증거 (Benign Evidence)**

#### **A. 단독 (BA1):**
- **평가:** 미충족  
- **근거:** gnomAD에서 대립유전자 빈도가 "None"으로, 5% 이상이 아닙니다.  

---

#### **B. 강력 (BS1-BS4):**
- **BS1:**  
  - **평가:** 미충족  
  - **근거:** 환자군에서의 유병률 증가 데이터가 제공되지 않았습니다.  

- **BS2:**  
  - **평가:** 미충족  
  - **근거:** 건강한 성인에서 관찰된 사례가 제공되지 않았습니다.  

- **BS3:**  
  - **평가:** 미충족  
  - **근거:** 기능 연구 데이터가 제공되지 않았습니다.  

- **BS4:**  
  - **평가:** 미충족  
  - **근거:** 가계 분리 데이터가 제공되지 않았습니다.  

---

#### **C. 지지 (BP1-BP7):**
- **BP1:**  
  - **평가:** 미충족  
  - **근거:** PAH는 LOF 기전이 주요한 유전자이지만, 이 변이는 missense이므로 BP1에 해당하지 않습니다.  

- **BP2:**  
  - **평가:** 미충족  
  - **근거:** trans에서 병원성 변이와 동반된 사례가 제공되지 않았습니다.  

- **BP3:**  
  - **평가:** 미충족  
  - **근거:** in-frame indel이 아닙니다.  

- **BP4:**  
  - **평가:** 미충족  
  - **근거:** CADD/REVEL은 고위험 예측을 보여줍니다.  

- **BP5:**  
  - **평가:** 미충족  
  - **근거:** 대체 분자적 근거가 있는 증례가 제공되지 않았습니다.  

- **BP6:**  
  - **평가:** 미충족  
  - **근거:** 신뢰할 수 있는 출처에서 "양성"으로 분류된 사례가 제공되지 않았습니다.  

- **BP7:**  
  - **평가:** 미충족  
  - **근거:** SpliceAI 데이터가 "N/A"로, 스플라이스 영향 예측이 제공되지 않았습니다.  

---

### **3. 최종 분류**

#### **적용된 기준 요약:**
- **병원성:**  
  - PM2 (중등도)  
  - PP3 (지지)  
  - PP5 (지지)  

- **양성:**  
  - 없음  

---

#### **분류 규칙 (ACMG/AMP 2015):**
- **Likely Pathogenic:**  
  - 조건 (i): **PVS1 + PM** → 미충족  
  - 조건 (ii): **PS1 + PM** → 미충족  
  - 조건 (iii): **PM2 (중등도) + PP3 (지지) + PP5 (지지)** → 충족  
  - 조건 (iv): **PS1 + PS2** → 미충족  
  - 조건 (v): **PM2 (중등도) + PP3 (지지) + PP5 (지지)** → 충족  

---

#### **최종 분류:**
- **분류:** **Likely Pathogenic**  
- **신뢰도:** **높음**  
- **해석 요약:**  
  - PAH 유전자에서의 **p.Phe121Val** missense 변이는 gnomAD에서 극히 드물거나 부재 (PM2)하며, ClinVar에서 "Likely_pathogenic"으로 분류 (PP5)되었습니다.  
  - CADD (0.99)와 REVEL (0.99)는 **고위험** 예측을 보여줍니다 (PP3).  
  - 이 변이는 **PKU (phenylketonuria)**와 관련된 유전자에서의 병원성 변이로 해석됩니다.  

- **권고사항:**  
  - 추가적인 **가계 분리 데이터** 또는 **기능 연구** (in vitro/in vivo)가 있다면 분류를 재검토할 수 있습니다.  
  - 환자의 **임상 증상** (예: 고페닐알라닌혈증, 지능 저하 등)이 PAH와 일치하는지 확인하는 것이 중요합니다.  

--- 

### **결론:**
이 변이는 **Likely Pathogenic**으로 분류되며, PKU의 유전적 원인으로 간주됩니다. 신뢰도는 높으나, 추가적인 임상/분자적 증거가 있다면 분류를 재검토할 수 있습니다.